Cytosorbents Corporation
CTSO
$1.10
-$0.06-5.17%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 29.16% | 17.19% | 0.67% | 9.28% | 10.87% |
| Total Depreciation and Amortization | -13.80% | 39.33% | 61.29% | 84.97% | 78.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -- |
| Total Other Non-Cash Items | 192.71% | 39.36% | 218.26% | -5.10% | -58.35% |
| Change in Net Operating Assets | -265.28% | -564.60% | -475.10% | -222.11% | 174.38% |
| Cash from Operations | 33.37% | 10.18% | 3.97% | -0.66% | 23.30% |
| Capital Expenditure | 47.18% | 52.66% | 73.88% | 98.75% | 91.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.29% | -5.74% | -8.76% | 24.03% | -8.12% |
| Cash from Investing | 28.49% | 32.31% | 56.29% | 93.95% | 85.50% |
| Total Debt Issued | -- | 200.00% | 200.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.48% | 441.75% | 699.31% | 1,922.96% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -35.54% | 194.26% | 234.40% | 132.54% | 191.84% |
| Foreign Exchange rate Adjustments | 15.13% | -156.29% | -202.60% | 27.74% | 62.05% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 28.79% | 114.96% | 100.61% | 55.60% | 72.60% |